Pharynx and esophagus: PET/CT

Jonathan E. McConathy; Farrokh Dehdashti

doi:10.1007/978-3-642-13327-5_195

Pharynx and esophagus: PET/CT

Jonathan E. McConathy
, Farrokh Dehdashti

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

This chapter reviews important considerations for the performance and interpretation of [¹⁸F]fluorodeoxyglucose (FDG)-PET/CT in the diagnostic evaluation of patients with esophageal cancer. Accurate staging is the primary basis for selecting appropriate treatment for patients with esophageal cancer. Attention to patient preparation, imaging protocols, potential artifacts and diagnostic pitfalls are critical for performing high quality FDG-PET/CT studies. The most established role of FDG-PET/CT in esophageal cancer is for staging of disease, particularly for the detection of distant metastatic disease. There is also evidence that FDG-PET/CT can be used to evaluate response to neoadjuvant therapy, although the impact on patient outcomes is not yet well-established.

Original language	English
Title of host publication	Abdominal Imaging
Publisher	Springer-Verlag Berlin Heidelberg
Pages	27-44
Number of pages	18
ISBN (Electronic)	9783642133275
ISBN (Print)	3642133266, 9783642133268
DOIs	https://doi.org/10.1007/978-3-642-13327-5_195
State	Published - Nov 1 2013

Access to Document

10.1007/978-3-642-13327-5_195

Cite this

@inbook{02d658e74d79426fac59e6855af32312,

title = "Pharynx and esophagus: PET/CT",

abstract = "This chapter reviews important considerations for the performance and interpretation of [18F]fluorodeoxyglucose (FDG)-PET/CT in the diagnostic evaluation of patients with esophageal cancer. Accurate staging is the primary basis for selecting appropriate treatment for patients with esophageal cancer. Attention to patient preparation, imaging protocols, potential artifacts and diagnostic pitfalls are critical for performing high quality FDG-PET/CT studies. The most established role of FDG-PET/CT in esophageal cancer is for staging of disease, particularly for the detection of distant metastatic disease. There is also evidence that FDG-PET/CT can be used to evaluate response to neoadjuvant therapy, although the impact on patient outcomes is not yet well-established.",

author = "McConathy, \{Jonathan E.\} and Farrokh Dehdashti",

note = "Publisher Copyright: {\textcopyright} 2013 Springer-Verlag Berlin Heidelberg. All rights are reserved.",

year = "2013",

month = nov,

day = "1",

doi = "10.1007/978-3-642-13327-5\_195",

language = "English",

isbn = "3642133266",

pages = "27--44",

booktitle = "Abdominal Imaging",

publisher = "Springer-Verlag Berlin Heidelberg",

}

TY - CHAP

T1 - Pharynx and esophagus

T2 - PET/CT

AU - McConathy, Jonathan E.

AU - Dehdashti, Farrokh

PY - 2013/11/1

Y1 - 2013/11/1

N2 - This chapter reviews important considerations for the performance and interpretation of [18F]fluorodeoxyglucose (FDG)-PET/CT in the diagnostic evaluation of patients with esophageal cancer. Accurate staging is the primary basis for selecting appropriate treatment for patients with esophageal cancer. Attention to patient preparation, imaging protocols, potential artifacts and diagnostic pitfalls are critical for performing high quality FDG-PET/CT studies. The most established role of FDG-PET/CT in esophageal cancer is for staging of disease, particularly for the detection of distant metastatic disease. There is also evidence that FDG-PET/CT can be used to evaluate response to neoadjuvant therapy, although the impact on patient outcomes is not yet well-established.

AB - This chapter reviews important considerations for the performance and interpretation of [18F]fluorodeoxyglucose (FDG)-PET/CT in the diagnostic evaluation of patients with esophageal cancer. Accurate staging is the primary basis for selecting appropriate treatment for patients with esophageal cancer. Attention to patient preparation, imaging protocols, potential artifacts and diagnostic pitfalls are critical for performing high quality FDG-PET/CT studies. The most established role of FDG-PET/CT in esophageal cancer is for staging of disease, particularly for the detection of distant metastatic disease. There is also evidence that FDG-PET/CT can be used to evaluate response to neoadjuvant therapy, although the impact on patient outcomes is not yet well-established.

UR - https://www.scopus.com/pages/publications/84927571707

U2 - 10.1007/978-3-642-13327-5_195

DO - 10.1007/978-3-642-13327-5_195

M3 - Chapter

AN - SCOPUS:84927571707

SN - 3642133266

SN - 9783642133268

SP - 27

EP - 44

BT - Abdominal Imaging

PB - Springer-Verlag Berlin Heidelberg

ER -

Pharynx and esophagus: PET/CT

Abstract

Access to Document

Other files and links

Fingerprint

Cite this